Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.

× No keyword cloud information.

18 in total

1. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.

Authors: Shiwen Peng; Sofia Lyford-Pike; Belinda Akpeng; Annie Wu; Chien-Fu Hung; Drew Hannaman; John R Saunders; T-C Wu; Sara I Pai
Journal: Cancer Immunol Immunother Date: 2012-08-04 Impact factor: 6.968

Review 2. Chemotherapy and tumor immunity: an unexpected collaboration.

Authors: Leisha A Emens
Journal: Front Biosci Date: 2008-01-01

3. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting.

Authors: Tomoharu Miyashita; Furhawn A Shah; Guy Marti; Jiaai Wang; Todd Armstrong; Pramod Bonde; Michael K Gibson; Kiyoshi Yoshimura; Elizabeth A Montgomery; Mark D Duncan; Elizabeth M Jaffee; John W Harmon
Journal: J Gastrointest Surg Date: 2007-10-24 Impact factor: 3.452

4. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting.

Authors: Tomoharu Miyashita; Furhawn A Shah; Guy P Marti; Todd D Armstrong; Jiaai Wang; Pramod Bonde; Michael K Gibson; Kiyoshi Yoshimura; Elizabeth A Montgomery; Mark Duncan; Elizabeth M Jaffee; John W Harmon
Journal: Dig Dis Sci Date: 2008-03-15 Impact factor: 3.199

5. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.

Authors: M Zahidunnabi Dewan; Claire Vanpouille-Box; Noriko Kawashima; Sara DiNapoli; James S Babb; Silvia C Formenti; Sylvia Adams; Sandra Demaria
Journal: Clin Cancer Res Date: 2012-10-09 Impact factor: 12.531

6. A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma.

Authors: Chen Chen; Jiajie Hou; Zhe Lin; Ming Yao; Runqiu Jiang; Youjing Wang; Yun Gao; Qing Shao; Lei Deng; Yun Chen; Beicheng Sun
Journal: Cell Mol Immunol Date: 2013-05-20 Impact factor: 11.530

7. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Authors: Satoshi Wada; Kiyoshi Yoshimura; Edward L Hipkiss; Tim J Harris; Hung-Rong Yen; Monica V Goldberg; Joseph F Grosso; Derese Getnet; Angelo M Demarzo; George J Netto; Robert Anders; Drew M Pardoll; Charles G Drake
Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701

Review 8. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Authors: Sanjay Srivatsan; Jaina M Patel; Erica N Bozeman; Imade E Imasuen; Sara He; Danielle Daniels; Periasamy Selvaraj
Journal: Hum Vaccin Immunother Date: 2013-09-24 Impact factor: 3.452

Review 9. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Authors: Ulf Petrausch; Christian H Poehlein; Shawn M Jensen; Chris Twitty; James A Thompson; Ilka Assmann; Sachin Puri; Michael G LaCelle; Tarsem Moudgil; Levi Maston; Kevin Friedman; Sarah Church; Elisa Cardenas; Daniel P Haley; Edwin B Walker; Emmanuel Akporiaye; Andrew D Weinberg; Sidney Rosenheim; Todd S Crocenzi; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Bernard A Fox
Journal: Curr Mol Med Date: 2009-08 Impact factor: 2.222

10. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects.

Authors: Emmanuel S Antonarakis; Michael A Carducci
Journal: Expert Opin Investig Drugs Date: 2010-02 Impact factor: 6.206